A Mitochondrion‐Targeted NIR‐II Modulator for Synergistic Ferroptosis–Immunotherapy
Small · 2025-06 · 21 (22)
DOI: 10.1002/smll.202501397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 14.04.2025. Verfasst von Miao Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tum…. Hauptthemen laut MEDLINE: Ferroptosis, Mitochondria, Immunotherapy, Infrared Rays. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shenzhen Science and Technology Research Grant.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have limited clinical efficacy against gastric cancer (GC) due to the nonimmunogenic tumor microenvironment. Therefore, inducing immunogenic cell death (ICD) to reprogram the immunogenic landscape is essential. This study develops HD‐FA nanoparticles by encapsulating a novel mitochondrion‐targeted NIR‐II modulator, HD, within DSPE‐PEG‐FA. HD‐FA exhibits superior spatiotemporal resolution, robust tumor accumulation, and minimal adverse effects. Upon 808 nm laser irradiation, HD‐FA generates reactive oxygen species, leading to ferroptosis and oxidative stress damage in GC cells by inhibiting the SLC7A11/GSH/GPX4 axis. HD‐FA triggers ICD, resulting in antitumor activity not only in primary tumors but also in distant tumors. Moreover, HD‐FA promotes dendritic cell maturation, increases the effector‐memory T‐cell frequency, and reduces the presence of myeloid‐derived suppressor cells, thereby fostering enhanced antitumor immunity. This study presents the first report of a novel NIR‐II modulator for GC immunogenic synergistic therapy with ICIs, marking significant advancements in the fight against GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, School of Pharmaceutical Sciences, Wuhan, 430…
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, China.
- Department of Chemistry, Korea University, Seoul, 02841, South Korea.
- Shenzhen Institute of Wuhan University, Shenzhen, 518057, China.
- Department of Dermatology, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
ORCID-Profile: Qihang Ding, Yuling Xiao
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shenzhen Science and Technology Research Grant
- Guangdong Basic and Applied Basic Research Foundation
- Tibet Autonomous Region Science and Technology Plan Project Key Project
- Natural Science Foundation of Shandong Province
- Shandong Laboratory Program
- Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University
Zitieren
APA
Wang, M., Ding, Q., Su, W., Luo, M., Yang, R., Chen, G., Wang, Q., Zhang, N., Gao, J., Wang, X., Huang, T., Liu, P., Fu, D., Hong, X., Zeng, X., Wei, Y., & Xiao, Y. (2025). A Mitochondrion‐Targeted NIR‐II Modulator for Synergistic Ferroptosis–Immunotherapy. Small, 21(22). https://doi.org/10.1002/smll.202501397
Vancouver
Wang M, Ding Q, Su W, Luo M, Yang R, Chen G, et al. A Mitochondrion‐Targeted NIR‐II Modulator for Synergistic Ferroptosis–Immunotherapy. Small. 2025;21(22). doi:10.1002/smll.202501397
BibTeX
@article{Wang2025,
author = {Wang, Miao and Ding, Qihang and Su, Wuyue and Luo, Min and Yang, Runping and Chen, Guopeng and Wang, Qian and Zhang, Nan and Gao, Jialu and Wang, Xiaofen and Huang, Tianhe and Liu, Pan and Fu, Dujiang and Hong, Xuechuan and Zeng, Xiaodong and Wei, Yongchang and Xiao, Yuling},
title = {A Mitochondrion‐Targeted NIR‐II Modulator for Synergistic Ferroptosis–Immunotherapy},
journal = {Small},
year = {2025},
volume = {21},
number = {22},
doi = {10.1002/smll.202501397}
}
EUVIMED